BiotechTube
Home/Symberix/Matthew R. Redinbo, Ph.D.
MR

Matthew R. Redinbo, Ph.D.

Scientific Co-Founder

Symberix

Therapeutic Areas

Inflammatory DiseasesSupportive CareInfectious Diseases

Symberix Pipeline

DrugIndicationPhase
Microbiome-Sparing Enzyme InhibitorsDrug-induced toxicities (e.g., Chemotherapy-induced diarrhea)Preclinical